CN106715699A8 - 用于减弱抗病毒转移载体免疫应答的方法和组合物 - Google Patents
用于减弱抗病毒转移载体免疫应答的方法和组合物 Download PDFInfo
- Publication number
- CN106715699A8 CN106715699A8 CN201580047585.5A CN201580047585A CN106715699A8 CN 106715699 A8 CN106715699 A8 CN 106715699A8 CN 201580047585 A CN201580047585 A CN 201580047585A CN 106715699 A8 CN106715699 A8 CN 106715699A8
- Authority
- CN
- China
- Prior art keywords
- weakening
- transfer vector
- composition
- immune response
- vector immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000003313 weakening effect Effects 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 241000701447 unidentified baculovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Theoretical Computer Science (AREA)
- Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
Abstract
Applications Claiming Priority (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047051P | 2014-09-07 | 2014-09-07 | |
US201462047034P | 2014-09-07 | 2014-09-07 | |
US201462047044P | 2014-09-07 | 2014-09-07 | |
US201462047054P | 2014-09-07 | 2014-09-07 | |
US62/047,051 | 2014-09-07 | ||
US62/047,034 | 2014-09-07 | ||
US62/047,054 | 2014-09-07 | ||
US62/047,044 | 2014-09-07 | ||
US201462051267P | 2014-09-16 | 2014-09-16 | |
US201462051258P | 2014-09-16 | 2014-09-16 | |
US201462051255P | 2014-09-16 | 2014-09-16 | |
US201462051263P | 2014-09-16 | 2014-09-16 | |
US62/051,255 | 2014-09-16 | ||
US62/051,258 | 2014-09-16 | ||
US62/051,267 | 2014-09-16 | ||
US62/051,263 | 2014-09-16 | ||
US201562101841P | 2015-01-09 | 2015-01-09 | |
US201562101861P | 2015-01-09 | 2015-01-09 | |
US201562101882P | 2015-01-09 | 2015-01-09 | |
US201562101872P | 2015-01-09 | 2015-01-09 | |
US62/101,882 | 2015-01-09 | ||
US62/101,841 | 2015-01-09 | ||
US62/101,872 | 2015-01-09 | ||
US62/101,861 | 2015-01-09 | ||
PCT/US2015/048768 WO2016037162A1 (en) | 2014-09-07 | 2015-09-07 | Methods and compositions for attenuating anti-viral transfer vector immune responses |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106715699A CN106715699A (zh) | 2017-05-24 |
CN106715699A8 true CN106715699A8 (zh) | 2017-07-11 |
Family
ID=54291579
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580047807.3A Pending CN106714826A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
CN202111297024.4A Pending CN114146167A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
CN201580047634.5A Pending CN107073091A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物 |
CN201580047585.5A Pending CN106715699A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
CN201580047806.9A Pending CN107073050A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因治疗抗病毒转移载体免疫应答的方法和组合物 |
CN201580047633.0A Pending CN107075499A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因编辑抗病毒转移载体免疫应答的方法和组合物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580047807.3A Pending CN106714826A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
CN202111297024.4A Pending CN114146167A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
CN201580047634.5A Pending CN107073091A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580047806.9A Pending CN107073050A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因治疗抗病毒转移载体免疫应答的方法和组合物 |
CN201580047633.0A Pending CN107075499A (zh) | 2014-09-07 | 2015-09-07 | 用于减弱基因编辑抗病毒转移载体免疫应答的方法和组合物 |
Country Status (12)
Country | Link |
---|---|
US (7) | US10046064B2 (zh) |
EP (5) | EP3189138A4 (zh) |
JP (11) | JP7242179B2 (zh) |
KR (7) | KR20170045345A (zh) |
CN (6) | CN106714826A (zh) |
AU (10) | AU2015311704B2 (zh) |
BR (5) | BR112017001470A2 (zh) |
CA (5) | CA2957808A1 (zh) |
EA (5) | EA201790534A1 (zh) |
IL (10) | IL292580A (zh) |
MX (10) | MX2017002935A (zh) |
WO (5) | WO2016037165A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
EA023397B1 (ru) | 2010-05-26 | 2016-05-31 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012149259A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
EA201592103A3 (ru) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для усиления cd4+ регуляторных t-клеток |
MX2016007654A (es) | 2013-12-11 | 2017-08-15 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
JP7059179B2 (ja) * | 2015-10-20 | 2022-04-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子操作のための方法及び製品 |
EP3429632B1 (en) | 2016-03-16 | 2023-01-04 | CRISPR Therapeutics AG | Materials and methods for treatment of hereditary haemochromatosis |
US10751423B2 (en) | 2016-05-02 | 2020-08-25 | Massachusetts Institute Of Technology | Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer |
KR20190104194A (ko) * | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
US20230190958A1 (en) * | 2017-01-13 | 2023-06-22 | Jichi Medical University | AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome |
CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
MX2020003838A (es) * | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
MX2020007390A (es) * | 2018-01-11 | 2020-10-14 | Chameleon Biosciences Inc | Vectores immunoevasivos y uso para terapia genica. |
CA3106640A1 (en) * | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
WO2020055917A1 (en) * | 2018-09-10 | 2020-03-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating cln3 expression |
WO2020132595A1 (en) * | 2018-12-21 | 2020-06-25 | The Regents Of The University Of California | Il-10-containing vaccines and uses thereof |
US20220142991A1 (en) * | 2019-03-14 | 2022-05-12 | Children's Hospital Medical Center | Methods and compositions for treatment of l ysosomal storage disorder |
CN110055278B (zh) * | 2019-04-23 | 2021-10-15 | 深圳市弘际生物科技有限责任公司 | 一种新型腺病毒包装方法在CRISPR/Cas9基因编辑方法中的应用 |
MX2021013163A (es) * | 2019-04-28 | 2022-02-21 | Selecta Biosciences Inc | Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral. |
MX2021014566A (es) * | 2019-05-28 | 2022-03-22 | Selecta Biosciences Inc | Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral. |
CN110396524B (zh) * | 2019-05-31 | 2023-05-02 | 海南大学 | 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途 |
US20230233708A1 (en) * | 2020-04-14 | 2023-07-27 | University Of Florida Research Foundation, Incorporated | Enhancing aav-mediated delivery and transduction with polyvinyl alcohol |
CN113769058A (zh) * | 2020-06-10 | 2021-12-10 | 上海宝济药业有限公司 | 一种药物组合及其应用 |
CN112656763B (zh) * | 2020-12-29 | 2022-07-15 | 吉林大学 | 一种基于剪切力响应的载药纳米胶束的制备方法 |
WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
CN113876765A (zh) * | 2021-10-28 | 2022-01-04 | 青岛大学附属医院 | 蟛蜞菊内酯在制备用于预防和/或治疗疱疹病毒感染的药物和保健品中的应用 |
CN116875621B (zh) * | 2023-07-18 | 2024-03-29 | 浙江大学 | 一种提高转移载体中ires序列介导筛选基因表达效率的方法 |
Family Cites Families (329)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
EP0303681B1 (en) | 1987-02-24 | 1992-10-14 | Xoma Corporation | Immunosuppression in immunotoxin based human therapy |
US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
CN1263864C (zh) | 1993-10-25 | 2006-07-12 | 坎吉公司 | 重组腺病毒载体及其使用方法 |
TW249754B (zh) | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
CA2190494C (en) | 1994-05-18 | 2002-05-07 | Michael E. Houston | Heterodimer polypeptide immunogen carrier composition and method |
JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
WO1996012406A1 (en) * | 1994-10-19 | 1996-05-02 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
US6893664B1 (en) | 1996-06-17 | 2005-05-17 | Powderject Research Limited | Particle delivery techniques |
WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
WO1998010056A1 (en) | 1996-09-03 | 1998-03-12 | Health Research Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell function |
US5814500A (en) | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
SI20117A (sl) | 1996-12-27 | 2000-06-30 | Icn Pharmaceuticals, Inc. | Oligoaptameri bogati z G-jem in metode modulacije imunskega odziva |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
DE69820450T2 (de) | 1997-06-09 | 2004-05-27 | Genvec, Inc. | Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
EP0894853A1 (en) | 1997-07-24 | 1999-02-03 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Transcriptional silencer protein NRF, nucleic acid molecules encoding it and their use |
WO1999006583A1 (en) | 1997-07-31 | 1999-02-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
EP1015620B1 (en) | 1997-09-23 | 2005-08-31 | Genvec, Inc. | Dual selection cassette and plasmids containing same |
US6350590B1 (en) | 1997-10-30 | 2002-02-26 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
JP2001526900A (ja) | 1997-12-23 | 2001-12-25 | イントロヘーネ ベスローテン フェンノートシャップ | 標的細胞の染色体dnaへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス |
EP1044019A1 (en) | 1998-01-09 | 2000-10-18 | Circassia Limited | Methods and compositions for desensitisation |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
HUP0102209A2 (hu) | 1998-04-22 | 2001-09-28 | Genvec, Inc. | Eljárás adenovírus hatékony tisztítására |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
AU1201600A (en) | 1998-10-08 | 2000-04-26 | University Of Massachusetts | Controlling gene expression in living cells |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
DE19951970A1 (de) | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
AU4724401A (en) | 2000-02-28 | 2001-09-12 | Genesegues Inc | Nanocapsule encapsulation system and method |
WO2001068133A1 (en) | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
US6168941B1 (en) | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
AU2001265187A1 (en) | 2000-05-30 | 2001-12-11 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
AU2001269723B9 (en) | 2000-06-01 | 2006-11-16 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
US6447995B1 (en) | 2000-10-04 | 2002-09-10 | Genvec, Inc. | Utilizing intrinsic fluorescence to detect adenovirus |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
WO2002062949A2 (en) | 2000-10-20 | 2002-08-15 | Canji, Inc | Aptamer-mediated regulation of gene expression |
US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
AU2002338571A1 (en) | 2001-04-11 | 2002-11-11 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
EP1399183B1 (en) | 2001-05-31 | 2010-06-30 | Novartis Vaccines and Diagnostics, Inc. | Chimeric alphavirus replicon particles |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
JP4790984B2 (ja) | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
IL161229A0 (en) | 2001-10-02 | 2004-09-27 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications. |
PL210841B1 (pl) | 2001-10-19 | 2012-03-30 | Isotechnika Inc | Sposób wytwarzania mieszaniny izomerów (E) i (Z) ISATX247 |
DK1453547T3 (en) | 2001-12-17 | 2016-12-05 | Univ Pennsylvania | ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF |
GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
BR0305018A (pt) | 2002-06-04 | 2004-09-21 | Univ Pittsburgh | Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas |
CA2494508A1 (en) | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7238346B2 (en) | 2002-07-08 | 2007-07-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | High capacity recombinant adenoviral vector for treatment of hemophilia A |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
DK1565183T3 (da) | 2002-11-29 | 2008-12-01 | Maria Grazia Roncarolo | Rapamycin og IL-10 til behandling af autoimmune sygdomme |
WO2004054512A2 (en) | 2002-12-13 | 2004-07-01 | Genetix Pharmaceuticals, Inc. | Therapeutic retroviral vectors for gene therapy |
WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US8198020B2 (en) | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
WO2005038035A2 (en) | 2003-10-15 | 2005-04-28 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses |
JP2008504216A (ja) | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
DK1704585T3 (en) | 2003-12-19 | 2017-05-22 | Univ North Carolina Chapel Hill | Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography |
WO2005089224A2 (en) | 2004-03-12 | 2005-09-29 | Alnylam Pharmaceuticals, Inc. | iRNA AGENTS TARGETING VEGF |
CN1960726A (zh) | 2004-04-08 | 2007-05-09 | 应用研究系统Ars股份公司 | 包含jnk抑制剂和环孢菌素的组合物 |
EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
AU2005326322B2 (en) | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
FR2874384B1 (fr) * | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
DE602005027479D1 (de) | 2004-09-24 | 2011-05-26 | Alnylam Pharmaceuticals Inc | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai |
AU2005294420A1 (en) | 2004-10-05 | 2006-04-20 | Tanox, Inc. | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-IgE antibodies in patients receiving replacement therapy |
US7790878B2 (en) | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US20060089324A1 (en) | 2004-10-22 | 2006-04-27 | Sailen Barik | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
CN104083342A (zh) | 2004-12-31 | 2014-10-08 | 伊休蒂卡有限公司 | 纳米微粒组合物及其合成方法 |
EP2172549B1 (en) | 2005-02-03 | 2015-08-26 | Benitec, Inc. | RNAi expression constructs |
EP1858332A4 (en) | 2005-02-16 | 2011-06-22 | Lentigen Corp | LENTIVIRUS VECTORS AND ITS USE |
GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
US20080275076A1 (en) | 2005-03-08 | 2008-11-06 | Per Holm | Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof |
EP1868576A2 (en) | 2005-03-17 | 2007-12-26 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
EP1871343A2 (en) | 2005-04-12 | 2008-01-02 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
CA2608086A1 (en) | 2005-05-10 | 2006-11-16 | Emory University | Strategies for delivery of active agents using micelles and particles |
CA2609276A1 (en) | 2005-05-23 | 2006-11-30 | De-Chu C. Tang | Rapid production of adenovirus-free recombinant adenovirus vectors |
TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
JP5116107B2 (ja) | 2005-06-27 | 2013-01-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | HIF−1のRNAi調節及びその治療的利用 |
EP1932538A4 (en) | 2005-08-25 | 2009-10-21 | Taiho Pharmaceutical Co Ltd | BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID |
CN1979166A (zh) | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
EP1957082B1 (en) | 2005-12-02 | 2012-04-11 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
MX2008007287A (es) | 2005-12-08 | 2008-10-27 | Univ Louisville Res Found | Metodos y composiciones para expandir celulas reguladoras t. |
US20070249043A1 (en) | 2005-12-12 | 2007-10-25 | Mayall Timothy P | Adenoviral expression vectors |
GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
CA2640286C (en) | 2006-02-13 | 2018-01-02 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
US8568487B2 (en) | 2006-02-27 | 2013-10-29 | Biomet Manufacturing, Llc | Patient-specific hip joint devices |
TW200806789A (en) | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
WO2007127377A2 (en) | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease |
EP2019839B1 (en) | 2006-05-25 | 2011-12-07 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
DK2051987T3 (en) | 2006-08-18 | 2015-01-05 | Argos Therapeutics Inc | USE OF CD83 IN COMBINATION THERAPY |
US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
CN101583379B (zh) | 2006-10-05 | 2013-04-03 | 约翰斯霍普金斯大学 | 使用优良聚合物纳米粒子的水溶性差药物的水可分散性口服,肠胃外和局部制剂 |
WO2008043157A1 (en) | 2006-10-12 | 2008-04-17 | The University Of Queensland | Compositions and methods for modulating immune responses |
CN101646418B (zh) | 2006-10-12 | 2013-07-17 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
WO2008064357A2 (en) | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
MX2009006303A (es) | 2006-12-14 | 2009-10-21 | Dow Agrosciences Llc | Proteinas de dedo de zinc no canonicas optimizadas. |
WO2008083331A2 (en) | 2006-12-29 | 2008-07-10 | The Regents Of The University Of Colorado | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
EP3417859A1 (en) | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
JP5650406B2 (ja) | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
ES2400964T3 (es) | 2007-04-04 | 2013-04-15 | Sigmoid Pharma Limited | Composiciones famacéuticas de ciclosporina |
AU2008236566A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
WO2008127532A1 (en) | 2007-04-12 | 2008-10-23 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
AU2008242583B2 (en) | 2007-04-23 | 2013-10-10 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
AU2008258646A1 (en) | 2007-06-05 | 2008-12-11 | Fondazione Centro San Raffaele Del Monte Tabor | Induction of tolerogenic phenotype in mature dendritic cells |
US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
EP2185192B1 (en) | 2007-08-03 | 2018-10-31 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
WO2009022154A2 (en) | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with multiple epitopes |
US20090104114A1 (en) | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
CA2704383A1 (en) | 2007-10-31 | 2009-05-07 | James Jefferson Smith | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
CA2703079A1 (en) | 2007-12-07 | 2009-06-18 | Precision Biosciences, Inc. | Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome |
NZ587060A (en) * | 2007-12-31 | 2012-09-28 | Nanocor Therapeutics Inc | Rna interference for the treatment of heart failure |
EP2249900A4 (en) | 2008-02-08 | 2013-11-06 | Terumo Corp | DEVICE FOR LOCAL INTRALUMINAL TRANSPORT OF A BIOLOGICALLY AND PHYSIOLOGICALLY ACTIVE AGENCY |
WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
WO2009114321A2 (en) | 2008-03-11 | 2009-09-17 | Precision Biosciencs, Inc. | Rationally-designed meganucleases for maize genome engineering |
WO2009146179A1 (en) | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
WO2010005721A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2300022A2 (en) | 2008-04-25 | 2011-03-30 | Duke University | Regulatory b cells and their uses |
JP5727367B2 (ja) | 2008-05-15 | 2015-06-03 | ダイナバックス テクノロジーズ コーポレイション | 免疫賦活オリゴヌクレオチドを使用する長期疾患改良 |
WO2009145238A1 (ja) | 2008-05-27 | 2009-12-03 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US20110070154A1 (en) | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
WO2010018384A1 (en) | 2008-08-15 | 2010-02-18 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
US9216188B2 (en) | 2008-09-04 | 2015-12-22 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
EP2342321B1 (en) | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
EP3428278A1 (en) | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
US20100216804A1 (en) * | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
SG193843A1 (en) | 2009-01-20 | 2013-10-30 | Univ Northwestern | Compositions and methods for induction of antigen-specific tolerance |
EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
WO2010089554A1 (en) | 2009-02-05 | 2010-08-12 | Circassia Limited | Peptides for vaccine |
KR20100099849A (ko) | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
MX2011011134A (es) | 2009-04-21 | 2012-01-31 | Selecta Biosciences Inc | Agentes inmunonanoterapeuticos que proporcionan una respuesta sesgada hacia th1. |
EP2421563B1 (en) | 2009-04-22 | 2017-04-12 | Massachusetts Institute of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
EP3461840A1 (en) | 2009-04-27 | 2019-04-03 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis |
EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
EP3482768A1 (en) | 2009-06-25 | 2019-05-15 | Horizon Pharma Rheumatology LLC | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
EP3311833A3 (en) | 2009-08-26 | 2018-07-25 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
EP2480659A2 (en) | 2009-09-24 | 2012-08-01 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
CN101703781A (zh) | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
CN103003430A (zh) | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
AU2010327998B2 (en) | 2009-12-10 | 2015-11-12 | Iowa State University Research Foundation, Inc. | TAL effector-mediated DNA modification |
KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
CA2792258A1 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
MX337586B (es) | 2010-05-07 | 2016-03-11 | Xoma Us Llc | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. |
EA023397B1 (ru) | 2010-05-26 | 2016-05-31 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
CN105832703A (zh) | 2010-06-07 | 2016-08-10 | 阿布拉科斯生物科学有限公司 | 治疗增殖性疾病的联合治疗方法 |
EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012024621A2 (en) | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin |
AU2011293508A1 (en) | 2010-08-23 | 2013-01-24 | Selecta Biosciences, Inc. | Targeted multi-epitope dosage forms for induction of an immune response to antigens |
CA2810842C (en) | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Macrolide dosage forms |
WO2012054920A2 (en) | 2010-10-22 | 2012-04-26 | University Of Florida Research Foundation, Inc. | Antigen-specific, tolerance-inducing microparticles and uses thereof |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
KR20140052963A (ko) * | 2011-02-08 | 2014-05-07 | 더 샬롯테-맥클렌버그 하스피털 오쏘러티 디/비/에이 카롤리나스 헬스케어 시스템 | 안티센스 올리고뉴클레오티드 |
ES2685611T3 (es) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo |
US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
EA201391392A1 (ru) | 2011-03-25 | 2014-04-30 | Селекта Байосайенсиз, Инк. | Синтетические наноносители с осмотически опосредованным высвобождением |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
EP2699688A1 (en) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
WO2012149259A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
RU2674036C2 (ru) | 2011-05-16 | 2018-12-04 | Джензим Корпорейшн | Индукция иммунологической толерантности, используя метотрексат |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
WO2013036296A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers |
WO2013036914A1 (en) | 2011-09-08 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating immune responses |
US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EA201490531A1 (ru) | 2011-10-11 | 2014-08-29 | Алиофта Аг | Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции |
WO2013058812A1 (en) | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
KR20220045091A (ko) | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법 |
CA2856137A1 (en) | 2011-11-22 | 2013-05-30 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
AU2013221212B2 (en) * | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
KR101833589B1 (ko) | 2012-02-24 | 2018-03-02 | 프레드 헛친슨 켄서 리서치 센터 | 이상혈색소증 치료를 위한 조성물 및 방법 |
CN103316356B (zh) | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
EP3663395A1 (en) | 2012-03-26 | 2020-06-10 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Delivery of packaged rna to mammalian cells |
BR112014025985A2 (pt) | 2012-04-18 | 2017-07-11 | Childrens Hospital Philadelphia | composição e métodos para transferência de gene altamente eficaz com o uso de variantes de capsídeo de aav |
CN109876139A (zh) | 2012-04-24 | 2019-06-14 | 俄亥俄州国家创新基金会 | 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法 |
US9738879B2 (en) | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
CA2879683C (en) | 2012-08-03 | 2023-02-14 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9499817B2 (en) | 2012-09-06 | 2016-11-22 | The University Of Chicago | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies |
EP2895611A4 (en) | 2012-09-14 | 2016-04-27 | Univ California | LENTIVIRAL VECTORS FOR STEM CELL GENE THERAPY OF SICKEN LEMENIA |
US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
CN102871966B (zh) | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
CN116966162A (zh) | 2013-03-13 | 2023-10-31 | onCOUR制药股份有限公司 | 用于治疗炎症的免疫修饰性颗粒 |
NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
BR112015023793A2 (pt) | 2013-03-15 | 2017-07-18 | Us Dept Veterans Affairs | composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a |
CA3174963A1 (en) | 2013-04-08 | 2014-10-16 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
WO2014179771A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
EA201592103A3 (ru) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для усиления cd4+ регуляторных t-клеток |
UY35582A (es) | 2013-05-22 | 2014-10-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |
US9873907B2 (en) | 2013-05-29 | 2018-01-23 | Agilent Technologies, Inc. | Method for fragmenting genomic DNA using CAS9 |
CN112933218A (zh) | 2013-06-04 | 2021-06-11 | 西莱克塔生物科技公司 | 非免疫抑制性抗原特异性免疫治疗剂的重复施用 |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
WO2015051199A2 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US9300930B2 (en) * | 2014-02-18 | 2016-03-29 | Microvision, Inc. | Multi-segment brightness compensation |
US10737320B2 (en) * | 2014-02-27 | 2020-08-11 | Ningxia Orient Tantalum Industry Co., Ltd. | High-purity tantalum powder and preparation method thereof |
US10339920B2 (en) * | 2014-03-04 | 2019-07-02 | Amazon Technologies, Inc. | Predicting pronunciation in speech recognition |
EP2916319A1 (en) * | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
EP3116900B1 (en) | 2014-03-09 | 2020-07-08 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |
GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
EA201692512A1 (ru) | 2014-06-25 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки |
CN106714826A (zh) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物 |
SI3215133T1 (sl) | 2014-11-05 | 2021-07-30 | Selecta Biosciences, Inc. | Postopki in sestavki v zvezi z uporabo površinsko aktivnih snovi z nizkim HLB v proizvodnji sintetičnih nanonosilcev, ki vsebujejo rapalog |
WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
CA3013896A1 (en) | 2016-02-10 | 2017-08-17 | Pfizer Inc. | Therapeutic nanoparticles having egfr ligands and methods of making and using same |
EP3426285B1 (en) | 2016-03-11 | 2024-05-29 | Cartesian Therapeutics, Inc. | Formulations and doses of pegylated uricase |
US10545815B2 (en) * | 2016-08-03 | 2020-01-28 | Futurewei Technologies, Inc. | System and method for data redistribution in a database |
WO2018039465A1 (en) | 2016-08-25 | 2018-03-01 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
EP3565605A1 (en) | 2017-01-03 | 2019-11-13 | ethris GmbH | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
EP3758677A1 (en) | 2018-02-26 | 2021-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
EP3790592A1 (en) | 2018-05-09 | 2021-03-17 | Yale University | Particles for spatiotemporal release of agents |
CA3106640A1 (en) | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
US20200038462A1 (en) | 2018-07-16 | 2020-02-06 | Selecta Biosciences, Inc. | Methods and compositions of otc constructs and vectors |
MX2021013163A (es) | 2019-04-28 | 2022-02-21 | Selecta Biosciences Inc | Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral. |
MX2021014566A (es) | 2019-05-28 | 2022-03-22 | Selecta Biosciences Inc | Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral. |
CN114207440A (zh) | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
AU2020370129A1 (en) | 2019-10-21 | 2022-05-12 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
WO2021092354A1 (en) | 2019-11-08 | 2021-05-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
MX2022011248A (es) | 2020-03-11 | 2022-12-15 | Selecta Biosciences Inc | Metodos y composiciones relacionados con nanoportadores sinteticos. |
-
2015
- 2015-09-07 CN CN201580047807.3A patent/CN106714826A/zh active Pending
- 2015-09-07 US US14/846,967 patent/US10046064B2/en active Active
- 2015-09-07 IL IL292580A patent/IL292580A/en unknown
- 2015-09-07 JP JP2017513047A patent/JP7242179B2/ja active Active
- 2015-09-07 KR KR1020177009111A patent/KR20170045345A/ko not_active IP Right Cessation
- 2015-09-07 MX MX2017002935A patent/MX2017002935A/es unknown
- 2015-09-07 CN CN202111297024.4A patent/CN114146167A/zh active Pending
- 2015-09-07 MX MX2017002931A patent/MX2017002931A/es unknown
- 2015-09-07 IL IL292575A patent/IL292575A/en unknown
- 2015-09-07 KR KR1020177009112A patent/KR20170045346A/ko not_active Application Discontinuation
- 2015-09-07 EP EP15838667.2A patent/EP3189138A4/en active Pending
- 2015-09-07 AU AU2015311704A patent/AU2015311704B2/en active Active
- 2015-09-07 EA EA201790534A patent/EA201790534A1/ru unknown
- 2015-09-07 US US14/846,952 patent/US20160074531A1/en active Pending
- 2015-09-07 EP EP15837503.0A patent/EP3193896A4/en active Pending
- 2015-09-07 AU AU2015311708A patent/AU2015311708A1/en not_active Abandoned
- 2015-09-07 EA EA201790532A patent/EA201790532A1/ru unknown
- 2015-09-07 EP EP15837338.1A patent/EP3188742A4/en active Pending
- 2015-09-07 JP JP2017512898A patent/JP7272746B2/ja active Active
- 2015-09-07 MX MX2017002933A patent/MX2017002933A/es unknown
- 2015-09-07 CN CN201580047634.5A patent/CN107073091A/zh active Pending
- 2015-09-07 WO PCT/US2015/048771 patent/WO2016037165A1/en active Application Filing
- 2015-09-07 KR KR1020177009109A patent/KR20170045344A/ko not_active IP Right Cessation
- 2015-09-07 BR BR112017001470A patent/BR112017001470A2/pt not_active Application Discontinuation
- 2015-09-07 KR KR1020177009113A patent/KR20170045347A/ko not_active Application Discontinuation
- 2015-09-07 JP JP2017513048A patent/JP7242180B2/ja active Active
- 2015-09-07 EP EP15778406.7A patent/EP3189147A1/en active Pending
- 2015-09-07 MX MX2017002932A patent/MX2017002932A/es unknown
- 2015-09-07 CA CA2957808A patent/CA2957808A1/en active Pending
- 2015-09-07 BR BR112017001311A patent/BR112017001311A2/pt active Search and Examination
- 2015-09-07 KR KR1020177009110A patent/KR20170054434A/ko not_active Application Discontinuation
- 2015-09-07 CA CA2957793A patent/CA2957793A1/en active Pending
- 2015-09-07 IL IL250865A patent/IL250865B2/en unknown
- 2015-09-07 MX MX2017002934A patent/MX2017002934A/es unknown
- 2015-09-07 JP JP2017513038A patent/JP7242178B2/ja active Active
- 2015-09-07 EP EP15778405.9A patent/EP3189146A1/en active Pending
- 2015-09-07 CN CN201580047585.5A patent/CN106715699A/zh active Pending
- 2015-09-07 WO PCT/US2015/048770 patent/WO2016037164A1/en active Application Filing
- 2015-09-07 CA CA2957800A patent/CA2957800A1/en active Pending
- 2015-09-07 BR BR112017001601A patent/BR112017001601A2/pt not_active Application Discontinuation
- 2015-09-07 AU AU2015311706A patent/AU2015311706A1/en not_active Abandoned
- 2015-09-07 KR KR1020237012024A patent/KR20230053710A/ko active IP Right Grant
- 2015-09-07 WO PCT/US2015/048767 patent/WO2016037161A2/en active Application Filing
- 2015-09-07 AU AU2015311705A patent/AU2015311705B2/en active Active
- 2015-09-07 JP JP2017512897A patent/JP7242177B2/ja active Active
- 2015-09-07 IL IL309546A patent/IL309546A/en unknown
- 2015-09-07 US US14/846,964 patent/US10071114B2/en active Active
- 2015-09-07 BR BR112017001245A patent/BR112017001245A2/pt not_active Application Discontinuation
- 2015-09-07 IL IL292577A patent/IL292577A/en unknown
- 2015-09-07 WO PCT/US2015/048769 patent/WO2016037163A1/en active Application Filing
- 2015-09-07 AU AU2015311707A patent/AU2015311707B2/en active Active
- 2015-09-07 CA CA2957737A patent/CA2957737A1/en active Pending
- 2015-09-07 BR BR112017001359A patent/BR112017001359A2/pt not_active Application Discontinuation
- 2015-09-07 CN CN201580047806.9A patent/CN107073050A/zh active Pending
- 2015-09-07 EA EA201790550A patent/EA201790550A1/ru unknown
- 2015-09-07 CA CA2957802A patent/CA2957802A1/en active Pending
- 2015-09-07 WO PCT/US2015/048768 patent/WO2016037162A1/en active Application Filing
- 2015-09-07 EA EA201790533A patent/EA201790533A1/ru unknown
- 2015-09-07 US US14/846,949 patent/US11633422B2/en active Active
- 2015-09-07 US US14/846,958 patent/US20160074532A1/en active Pending
- 2015-09-07 EA EA201790551A patent/EA201790551A1/ru unknown
- 2015-09-07 CN CN201580047633.0A patent/CN107075499A/zh active Pending
- 2015-09-07 KR KR1020237012021A patent/KR20230053709A/ko not_active Application Discontinuation
- 2015-09-07 IL IL292574A patent/IL292574A/en unknown
-
2017
- 2017-03-01 IL IL250874A patent/IL250874B/en unknown
- 2017-03-01 IL IL250872A patent/IL250872B/en unknown
- 2017-03-01 IL IL250877A patent/IL250877B/en unknown
- 2017-03-01 IL IL250873A patent/IL250873B/en unknown
- 2017-03-06 MX MX2023003253A patent/MX2023003253A/es unknown
- 2017-03-06 MX MX2023003252A patent/MX2023003252A/es unknown
- 2017-03-06 MX MX2023003249A patent/MX2023003249A/es unknown
- 2017-03-06 MX MX2023003254A patent/MX2023003254A/es unknown
- 2017-03-06 MX MX2023003246A patent/MX2023003246A/es unknown
-
2018
- 2018-08-09 US US16/100,040 patent/US20190076458A1/en active Pending
-
2021
- 2021-01-29 JP JP2021012709A patent/JP7395522B2/ja active Active
- 2021-05-19 JP JP2021084913A patent/JP7425767B2/ja active Active
- 2021-05-19 JP JP2021084907A patent/JP2021152013A/ja active Pending
- 2021-05-19 JP JP2021084901A patent/JP2021176845A/ja active Pending
- 2021-05-19 JP JP2021084897A patent/JP2021152012A/ja active Pending
- 2021-05-25 AU AU2021203379A patent/AU2021203379A1/en active Pending
- 2021-05-25 AU AU2021203376A patent/AU2021203376A1/en active Pending
-
2022
- 2022-02-25 AU AU2022201323A patent/AU2022201323A1/en active Pending
- 2022-02-27 AU AU2022201350A patent/AU2022201350A1/en active Pending
- 2022-02-27 AU AU2022201349A patent/AU2022201349A1/en active Pending
-
2023
- 2023-03-17 US US18/185,891 patent/US20230364124A1/en active Pending
- 2023-08-28 JP JP2023137900A patent/JP2024004492A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
EP3707248A4 (en) | MODIFIED IMMUNE CELLS AND THEIR USES | |
EP3583220A4 (en) | PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM | |
IL262497A (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
EP3625263A4 (en) | ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES | |
WO2016077381A8 (en) | Anti-interleukin-33 antibodies and uses thereof | |
EP3596119A4 (en) | ANTI-PHF-TAU ANTIBODIES AND USES THEREOF | |
EP3389702A4 (en) | ANTI-LAG-3 ANTIBODIES AND USES THEREOF | |
EP3426288A4 (en) | ANTI-PACAP ANTIBODIES AND USES THEREOF | |
EP3328895A4 (en) | ANTI-PD-1 ANTIBODIES AND USES THEREOF | |
EP3186277A4 (en) | Antibodies, compositions, and uses | |
MY191581A (en) | Anti-pd-1 antibodies | |
WO2015153513A8 (en) | Anti-ox40 antibodies and methods of use | |
EP3307772A4 (en) | SPECIFIC ANTIBODIES OF TGF-BETA 3 AND METHODS AND USES THEREOF | |
EP3565596A4 (en) | PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS | |
EP3113798A4 (en) | Methods and compositions for modifying the immune response | |
EP3672636A4 (en) | PROCEDURES AND COMPOSITIONS RELATED TO ANTI-CHI3L1 ANTIBODY REAGENTS | |
CN106659716A8 (zh) | 阿吡莫德组合物及其使用方法 | |
EP3402520A4 (en) | Anti-pd-1 antibodies and uses thereof | |
EP3426297A4 (en) | GITR ANTIBODIES, METHODS AND USES | |
IL274809A (en) | Antibodies against CXCR5 and their preparations and uses | |
EP3583219A4 (en) | PROBIOTIC COMPOSITIONS AND USES THEREFORE | |
EP3562508A4 (en) | ANTI-BODY ANTI-LAIR1 AND THEIR USES | |
EP3277313A4 (en) | Agents and compositions for eliciting an immune response | |
EP3094341A4 (en) | Enolase 1 (eno1) compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 62/047,051 2014.09.07 US|62/047,054 2014.09.07 US|62/047,034 2014.09.07 US|62/047,044 2014.09.07 US|62/051,267 2014.09.16 US|62/051,263 2014.09.16 US|62/051,255 2014.09.16 US|62/051,258 2014.09.16 US|62/101,841 2015.01.09 US|62/101,861 2015.01.09 US|62/101,882 2015.01.09 US|62/101,872 2015.01.09 US False: 62/047,051 2014.09.07 US|62/047,054 2014.09.07 US|62/047,034 2014.09.07 US|62/047,044 2014.09.07 US|62/051,267 2014.09.16 US|62/051,263 2014.09.16 US|62/051,255 2014.09.16 US|62/051,258 2014.09.16 US|62/101,841 2015.01.09 US|62/101,861 2015.01.09 US Number: 21 Volume: 33 |
|
CI02 | Correction of invention patent application | ||
CI02 | Correction of invention patent application |
Correction item: Priority Correct: 62/047,051 2014.09.07 US|62/047,054 2014.09.07 US|62/047,034 2014.09.07 US|62/047,044 2014.09.07 US|62/051,267 2014.09.16 US|62/051,263 2014.09.16 US|62/051,255 2014.09.16 US|62/051,258 2014.09.16 US|62/101,841 2015.01.09 US|62/101,861 2015.01.09 US|62/101,882 2015.01.09 US|62/101,872 2015.01.09 US False: 62/047,051 2014.09.07 US|62/047,054 2014.09.07 US|62/047,034 2014.09.07 US|62/047,044 2014.09.07 US|62/051,267 2014.09.16 US|62/051,263 2014.09.16 US|62/051,255 2014.09.16 US|62/051,258 2014.09.16 US|62/101,841 2015.01.09 US|62/101,861 2015.01.09 US Number: 21 Page: The title page Volume: 33 |